Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced cancer: first human trial of SIM0609 begins

NCT ID NCT07265921

First seen Jan 07, 2026 · Last updated May 21, 2026 · Updated 20 times

Summary

This early-stage study is testing a new drug, SIM0609, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 232 participants will take part in this first-in-human trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hubei Cancer Hospital

    NOT_YET_RECRUITING

    Wuhan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu Province Hospital

    NOT_YET_RECRUITING

    Nanjing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Cancer Hospital

    NOT_YET_RECRUITING

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhongshan Hospital,Fudan University

    NOT_YET_RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.